The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...
But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
11h
GlobalData on MSNPfizer sets sights on Summit’s bispecific in combo with its ADCsPfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s ivonescimab in combination with several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results